Women’s Health Initiative and menopausal hormone management
DOI:
https://doi.org/10.12809/hkjgom.21.2.02Keywords:
Breast neoplasms, Climacteric, MenopauseAbstract
This review discusses the findings of the Women’s Health Initiative in 2002 and its updates in 2013. Risks and benefits of menopausal hormone therapy in terms of coronary heart disease, breast cancer, stroke, pulmonary embolism and venous thromboembolism, colorectal cancer, endometrial cancer, and hip fracture/osteoporosis are also discussed, as is prescription of menopausal hormone therapy to alleviate menopausal symptoms and optimise health.
References
Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up
from the nurses’ health study. N Engl J Med 1991;325:756-62.
Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
About WHI. Women’s Health Initiative. https://www.whi.org/page/about-whi Accessed 26 July 2020.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
Brown S. Shock, terror and controversy: how the media reacted to the Women’s Health Initiative. Climacteric 2012;15:275-80.
Pines A, Sturdee DW, MacLennan AH, Schneider HP, Burger H, Fenton A. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007;10:267-9.
Prentice RL, Pettinger M, Anderson GL. Statistical issues arising in the Women’s Health Initiative. Biometrics 2005;61:899-941.
U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137:834-9.
Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 2007;16:17-27.
Barbaglia G, Macià F, Comas M, et al. Trends in hormone therapy use before and after publication of the Women’s Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061-4.
Clinical Alert: NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. National Heart, Lung, and Blood Institute (NHLBI) website. https://www.nlm.nih.gov/databases/alerts/estrogen_progestin.html Accessed 26 July 2020.
Patel A, Norton R, MacMahon S. The HRT furore: getting the message right. Med J Aust 2002;177:345-6.
Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views 2017;18:109-14.
Bhavnani B. Women’s Health Initiative study. J Obstet Gynaecol Can 2002;24:689-90.
Mastorakos G, Sakkas EG, Xydakis AM, Creatsas G. Pitfalls of the WHIs: Women’s Health Initiative. Ann N Y Acad Sci 2006;1092:331-40.
Naftolin F, Taylor HS, Karas R, et al. The Women’s Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-501.
Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? Hum Reprod 2003;18:1992-9.
Buhling KJ, von Studnitz FS, Jantke A, Eulenburg C, Mueck AO. Attitude of German gynecologists towards prescribing HRT before and after the WHI study. Climacteric 2012;15:326-31.
Du Y, Dören M, Melchert HU, Scheidt-Nave C, Knopf H. Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003. BMC Womens Health 2007;7:19.
Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study Results. Menopause 2018;26:588-97.
Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172-7.
Bush TM, Bonomi AE, Nekhlyudov L, et al. How the Women’s Health Initiative (WHI) influenced physicians’ practice and attitudes. J Gen Intern Med 2007;22:1311-6.
North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-71.
Sturdee DW, Pines A; International Menopause Society Writing Group, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-20.
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-68.
Rosano G, Vitale C, Spoletini I, Fini M. Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy. Climacteric 2012;15:299-305.
Vitale C, Mercuro G, Cerquetani E, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008;28:348-52.
Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10.
Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7.
Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109-50.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728-53.
Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev 2015;3:CD002229.
Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241-9.
Menopausal Hormone Therapy Advice. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists website. https://ranzcog.edu.au/statementsguidelines Accessed 26 July 2020.
Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-93.
Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21.
Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
Barnes EL, Long MD. Colorectal cancer in women: hormone replacement therapy and chemoprevention. Climacteric 2012;15:250-5.
Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994;170:1213-23.
Watts NB, Cauley JA, Jackson RD, et al. No increase in fractures after stopping hormone therapy: results from the Women’s Health Initiative. J Clin Endocrinol Metab 2017;102:302-8.
Jane FM, Davis SR. A practitioner’s toolkit for managing the menopause. Climacteric 2014;17:564-79.
Manson JE, Kaunitz AM. Menopause management--getting clinical care back on track. N Engl J Med 2016;374:803-6.
Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Womens Health (Lond) 2019;15:1745506519864009.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159-68.
IMS Comment on the paper published by the Collaborative Group on Hormonal Factors in Breast Cancer in The Lancet. 29 August 2019. https://www.imsociety.org/wp-content/uploads/2020/07/ims-press-statement-2019-08-29-english.pdf Accessed 26 July 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Hong Kong Journal of Gynaecology, Obstetrics and Midwifery
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.
